• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

METYROSINE Drug Record

  • Summary
  • Interactions
  • Claims
  • METYROSINE chembl:CHEMBL1200862 Approved

    Alternate Names:

    METYROSINE
    L-588357-0
    MK-781
    METIROSINE
    DEMSER
    METHYLTYROSINE
    METIROSINUM
    METIROSIN
    (-)-ALPHA-METHYL-L-TYROSINE
    DEMSER®
    ALPHA-METHYL-P-TYROSINE
    Α-MPT
    Α-METHYL-L-P-TYROSINE
    ALPHA-METHYLTYROSINE
    ALPHA-METHYL-PARA-TYROSINE
    MÉTIROSINE
    ALPHA-METHYL-L-P-TYROSINE
    Α-METHYL-PARA-TYROSINE
    (–)-Α-METHYL-L-TYROSINE
    L-ALPHA-METHYLTYROSINE
    (S)-ALPHA-METHYLTYROSINE
    METIROSINA
    Α-METHYL-P-TYROSINE
    rxcui:266604
    drugbank:00765
    chemidplus:672-87-7
    chembl:CHEMBL1200862
    pubchem.compound:441350

    Drug Info:

    Drug Class catecholamine synthesis inhibitors
    Year of Approval 1979
    FDA Approval 1979
    Drug Class small molecule
    Drug Indications Catecholamine synthesis inhibitors
    (4 More Sources)

    Publications:

    Yoshimoto et al., 2005, L-dopa and dopamine enhance the formation of aggregates under proteasome inhibition in PC12 cells., FEBS Lett.
    Shore et al., 1975, On a prime role for newly synthesized dopamine in striatal function., Eur. J. Pharmacol.
    Nasrallah et al., 1977, Inhibition of dopamine synthesis in chronic schizophrenia. Clinical ineffectiveness of metyrosine., Arch. Gen. Psychiatry
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Moore et al., 1980, Influence of prolactin on dopaminergic neuronal systems in the hypothalamus., Fed. Proc.
    Peng et al., 2004, Effect of catecholamines on IL-2 production and NK cytotoxicity of rats in vitro., Acta Pharmacol. Sin.
    Won et al., 1993, Alpha-methyl-p-tyrosine reduces poly I:C-induced augmenting interferon production and splenic natural killer cell activity in mice., Pharmacology
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Sivitz et al., 1999, Sympathetic inhibition, leptin, and uncoupling protein subtype expression in normal fasting rats., Am. J. Physiol.
    Han et al., 1999, D2 autoreceptors are not involved in the down-regulation of the striatal dopamine transporter caused by alpha-methyl-p-tyrosine., Res. Commun. Mol. Pathol. Pharmacol.
    Wang et al., 2006, Secretion of brain-derived neurotrophic factor from PC12 cells in response to oxidative stress requires autocrine dopamine signaling., J. Neurochem.
  • METYROSINE   TH

    Interaction Score: 4.01

    Interaction Types & Directionality:
    binder
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tyrosine 3-hydroxylase inhibitor
    Direct Interaction yes
    Trial Name -

    PMIDs:
    15710413 1168577 17374 11752352 7409209


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • METYROSINE   UCP1

    Interaction Score: 3.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10516126


    Sources:
    NCI

  • METYROSINE   IFNA1

    Interaction Score: 2.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7685917


    Sources:
    NCI

  • METYROSINE   IL2

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15456539


    Sources:
    NCI

  • METYROSINE   SLC6A3

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10741383


    Sources:
    NCI

  • METYROSINE   BDNF

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16390493


    Sources:
    NCI

  • METYROSINE   CYP2C9

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • METYROSINE   CYP2C19

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • METYROSINE   CYP1A2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • METYROSINE   CYP2D6

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • METYROSINE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TEND: METYROSINE

    • Version: 01-August-2011

    Alternate Names:
    METYROSINE Primary Drug Name

    Drug Info:
    Year of Approval 1979
    Drug Class catecholamine synthesis inhibitors

    Publications:

  • TdgClinicalTrial: METYROSINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Catecholamine synthesis inhibitors
    Drug Class small molecule
    FDA Approval 1979

    Publications:

  • NCI: ALPHA-METHYL-P-TYROSINE

    • Version: 14-September-2017

    Alternate Names:
    C998 NCI drug code

    Drug Info:

    Publications:
    Han et al., 1999, D2 autoreceptors are not involved in the down-regulation of the striatal dopamine transporter caused by alpha-methyl-p-tyrosine., Res. Commun. Mol. Pathol. Pharmacol.
    Wang et al., 2006, Secretion of brain-derived neurotrophic factor from PC12 cells in response to oxidative stress requires autocrine dopamine signaling., J. Neurochem.
    Won et al., 1993, Alpha-methyl-p-tyrosine reduces poly I:C-induced augmenting interferon production and splenic natural killer cell activity in mice., Pharmacology

  • DTC: METYROSINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1200862 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • TTD: Metyrosine

    • Version: 2020.06.01

    Alternate Names:
    D0B3QM TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1200862

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1200862

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: metyrosine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21